193 related articles for article (PubMed ID: 22532675)
1. Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.
Yeh WW; Brassard LM; Miller CA; Basavapathruni A; Zhang J; Rao SS; Nabel GJ; Mascola JR; Letvin NL; Seaman MS
J Virol; 2012 Jul; 86(13):7052-9. PubMed ID: 22532675
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.
Burton SL; Kilgore KM; Smith SA; Reddy S; Hunter E; Robinson HL; Silvestri G; Amara RR; Derdeyn CA
Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10780-5. PubMed ID: 26261312
[TBL] [Abstract][Full Text] [Related]
3. Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.
Yeh WW; Rahman I; Hraber P; Coffey RT; Nevidomskyte D; Giri A; Asmal M; Miljkovic S; Daniels M; Whitney JB; Keele BF; Hahn BH; Korber BT; Shaw GM; Seaman MS; Letvin NL
J Virol; 2010 Jun; 84(12):6018-32. PubMed ID: 20357097
[TBL] [Abstract][Full Text] [Related]
4. Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys.
Nguyen QN; Martinez DR; Himes JE; Whitney Edwards R; Han Q; Kumar A; Mangan R; Nicely NI; Xie G; Vandergrift N; Shen X; Pollara J; Permar SR
Retrovirology; 2018 Mar; 15(1):24. PubMed ID: 29523166
[TBL] [Abstract][Full Text] [Related]
5. Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.
Rybarczyk BJ; Montefiori D; Johnson PR; West A; Johnston RE; Swanstrom R
J Virol; 2004 Apr; 78(7):3561-71. PubMed ID: 15016879
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
7. High-Resolution Sequencing of Viral Populations during Early Simian Immunodeficiency Virus Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.
Ita S; Hill AK; Lam EC; Dufort FJ; Yang X; Newman R; Leviyang S; Fofana IB; Johnson WE
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343575
[TBL] [Abstract][Full Text] [Related]
8. Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies.
Chackerian B; Rudensey LM; Overbaugh J
J Virol; 1997 Oct; 71(10):7719-27. PubMed ID: 9311856
[TBL] [Abstract][Full Text] [Related]
9. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
[TBL] [Abstract][Full Text] [Related]
10. Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses.
Kuwata T; Takaki K; Yoshimura K; Enomoto I; Wu F; Ourmanov I; Hirsch VM; Yokoyama M; Sato H; Matsushita S
J Virol; 2013 May; 87(10):5424-36. PubMed ID: 23468483
[TBL] [Abstract][Full Text] [Related]
11. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.
Schell JB; Rose NF; Bahl K; Diller K; Buonocore L; Hunter M; Marx PA; Gambhira R; Tang H; Montefiori DC; Johnson WE; Rose JK
J Virol; 2011 Jun; 85(12):5764-72. PubMed ID: 21490100
[TBL] [Abstract][Full Text] [Related]
12. Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques.
Wu F; Ourmanov I; Kuwata T; Goeken R; Brown CR; Buckler-White A; Iyengar R; Plishka R; Aoki ST; Hirsch VM
J Virol; 2012 Aug; 86(16):8835-47. PubMed ID: 22696650
[TBL] [Abstract][Full Text] [Related]
13. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.
Seaman MS; Leblanc DF; Grandpre LE; Bartman MT; Montefiori DC; Letvin NL; Mascola JR
Virology; 2007 Oct; 367(1):175-86. PubMed ID: 17599382
[TBL] [Abstract][Full Text] [Related]
14. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells.
Quinnan GV; Yu XF; Lewis MG; Zhang PF; Sutter G; Silvera P; Dong M; Choudhary A; Sarkis PT; Bouma P; Zhang Z; Montefiori DC; Vancott TC; Broder CC
J Virol; 2005 Mar; 79(6):3358-69. PubMed ID: 15731230
[TBL] [Abstract][Full Text] [Related]
15. Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.
Amos JD; Himes JE; Armand L; Gurley TC; Martinez DR; Colvin L; Beck K; Overman RG; Liao HX; Moody MA; Permar SR
J Virol; 2015 Sep; 89(18):9485-98. PubMed ID: 26157116
[TBL] [Abstract][Full Text] [Related]
16. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein.
Jurkiewicz E; Hunsmann G; Schäffner J; Nisslein T; Lüke W; Petry H
J Virol; 1997 Dec; 71(12):9475-81. PubMed ID: 9371609
[TBL] [Abstract][Full Text] [Related]
17. Characterization of neutralization epitopes of simian immunodeficiency virus (SIV) recognized by rhesus monoclonal antibodies derived from monkeys infected with an attenuated SIV strain.
Cole KS; Alvarez M; Elliott DH; Lam H; Martin E; Chau T; Micken K; Rowles JL; Clements JE; Murphey-Corb M; Montelaro RC; Robinson JE
Virology; 2001 Nov; 290(1):59-73. PubMed ID: 11883006
[TBL] [Abstract][Full Text] [Related]
18. Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant.
Sugimoto C; Nakayama EE; Shioda T; Villinger F; Ansari AA; Yamamoto N; Suzuki Y; Nagai Y; Mori K
J Gen Virol; 2008 Feb; 89(Pt 2):554-566. PubMed ID: 18198387
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Complement-Mediated Lysis of Simian Immunodeficiency Virus (SIV) and SIV-Infected Cells Reveals Sex Differences in Vaccine-Induced Immune Responses in Rhesus Macaques.
Miller-Novak LK; Das J; Musich TA; Demberg T; Weiner JA; Venzon DJ; Mohanram V; Vargas-Inchaustegui DA; Tuero I; Ackerman ME; Alter G; Robert-Guroff M
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021899
[TBL] [Abstract][Full Text] [Related]
20. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
